Please assess the completion status of the following clinical trial:

Trial Title: Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Type 1 Diabetes mellitus (T1DM)~* Central laboratory C-peptide \< 0.7 ng/ml (0.23 nmol/L)~* Insulin use for at least 12 months per patient reported or medical records~* Method of insulin administration (MDI or CSII) must have been unchanged for at least 3 months prior to screening~* Subjects must be on a total insulin dose of ≥ 0.3 U/kg/day for at least 3 months prior to screening~* If on MDI insulin administration, subject must be on ≥ 3x injections per day~* Screening Visit: Central laboratory HbA1c ≥ 7.7% and ≤ 11.0%~* Body mass index (BMI) ≥ 18.5 kg/m2~Exclusion Criteria:~* History of Type 2 Diabetes mellitus (T2DM) or maturity onset diabetes of the young (MODY), pancreatic surgery, or chronic pancreatitis that could result in decreased beta cell capacity~* Taking any non-insulin antihyperglicemic agent within 1 month prior to screening~* Taking GLP-1 receptor agonist within 2 months prior to screening for once weekly administration and within 1 month prior to screening for once or twice daily administration~* Taking metformin and/or thiazolidinediones within 2 months prior to screening~* History of diabetes ketoacidosis requiring medical intervention within 1 month prior to screening~* History of hospital admission for glycemic control (either hyperglycemia or hypoglycemia) within 1 month prior to screening~* Frequent episodes of severe hypoglycemia (more than one episode requiring medical assistance, emergency care), and/or glucagon therapy administered by a third-party individual within 1 month prior to screening~* History of Addison's disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin 5 mg (Type: EXPERIMENTAL): Dapagliflozin 5 mg tablet orally, once daily for 52 weeks
- Dapagliflozin 10 mg (Type: EXPERIMENTAL): Dapagliflozin 10 mg tablet orally, once daily for 52 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet orally, once daily for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).